
Human CMVIE1 297-305, TMYGGISLL
Description
About Human CMVIE1 297-305, TMYGGISLL
The Human Cytomegalovirus (HCMV) (strain AD169) Immediate early protein IE1 Peptide (IEDB: 65277) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Immediate early protein Peptide, H-TMYGGISLL-OH (Uniprot: P13202 aa: 297-305) from JPT is produced under strict quality control and quality management.
Human CMVIE1 297-305, TMYGGISLL - Specifications
- Peptide sequence: H-TMYGGISLL-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human CMVIE1 297-305, TMYGGISLL
References:
Read References with JPT’s Antigen Peptides
Human CMVIE1 297-305, TMYGGISLL has been described in:
Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype., J Infect Dis, 2002 (PMID: 11930311)
Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response., J Virol, 2003 (PMID: 12634406)
MHC class I-associated peptides derive from selective regions of the human genome., J Clin Invest, 2016 (PMID: 27841757)
Documentation
Documentation for Human CMVIE1 297-305, TMYGGISLL
Properties
Properties of Human CMVIE1 297-305, TMYGGISLL
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Human Cytomegalovirus (HCMV) |
Protein Name: | Immediate early protein |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human CMVIE1 297-305, TMYGGISLL
Information | Values |
---|---|
Sequence: | H-TMYGGISLL-OH |
Specifications: | 9mer peptide as TFA salt |